Contact through OTT webpage does not guarantee a second opinion visit at the site nor a slot in the specific clinical trial of interest.
Clinical trial details
A phase II, open-label, biomarker-guided study of Carboplatin efficacy in pretreated metastatic castration-resistant Prostate Cancer (mCRPC)-BioChiP
Identifier
CNIO-CP-2019-01
Sponsor
CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (CNIO)
Principal Investigator
JOAQUIN MATEO VALDERRAMA
Service
Oncology
Study details
Tumor type: PROSTATE
Stage: Advanced
Main Investigational Agent : Cytotoxic
Phase: II
Randomization: Non-randomized
Molecular details
Biomarker: DDR path alt
Biomarker criteria: Preferred
Prescreening: Local/Central
Additional study population requirements: cohort A: patients with known deletereous homologous recombination repair (HRR) defects
